{"id":18353,"date":"2023-05-29T23:52:00","date_gmt":"2023-05-29T15:52:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18353"},"modified":"2024-12-16T23:56:55","modified_gmt":"2024-12-16T15:56:55","slug":"moderna-establishes-usd-100-million-subsidiary-in-shanghai-to-expand-mrna-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18353","title":{"rendered":"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology"},"content":{"rendered":"\n

US-based vaccine manufacturer Moderna (NASDAQ: MRNA<\/a>) has registered a new subsidiary in the Minhang district of Shanghai with an investment of USD 100 million. The new unit is controlled by Moderna Biotech UK, and the legal representative is Christoph Brackmann, Moderna\u2019s vice-president of finance, as reported by a local media outlet.<\/p>\n\n\n\n

Moderna’s mRNA Technology and Global Impact<\/strong>
Moderna\u2019s mRNA technology was pivotal during the COVID-19 pandemic, with the company being the first to introduce a COVID-19 mRNA vaccine globally, in partnership with Germany’s BioNTech. To date, no overseas mRNA vaccine has been approved in China, and Moderna anticipates that single dosage combination vaccines for respiratory diseases, including influenza and COVID-19, will be a growing trend.<\/p>\n\n\n\n

Strategic Move for Chinese Market Approval<\/strong>
Establishing a local entity in China is expected to facilitate the approval process for Moderna\u2019s mRNA vaccines in the Chinese market. The company is currently developing a combination vaccine against COVID-19 and influenza, as well as a vaccine for the prevention of influenza and respiratory syncytial virus (RSV). Additionally, a triple vaccine targeting COVID-19, influenza, and RSV is in the early stages of development.<\/p>\n\n\n\n

Future Market Expectations and Broader mRNA Applications<\/strong>
Paul Burton, chief medical officer of Moderna, has indicated that the combination vaccine is expected to be available in the US market as early as 2025. Beyond respiratory diseases, Moderna is also exploring the development of mRNA vaccines as new solutions for a range of conditions, including cancer and heart disease.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[203,63,1014,12],"class_list":["post-18353","post","type-post","status-publish","format-standard","hentry","category-company","tag-moderna","tag-mrna","tag-nasdaq-mrna","tag-vaccine"],"yoast_head":"\nModerna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district of Shanghai with an investment of USD 100 million. The new unit is controlled by Moderna Biotech UK, and the legal representative is Christoph Brackmann, Moderna\u2019s vice-president of finance, as reported by a local media outlet.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18353\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18353\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-29T15:52:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-16T15:56:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18353#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18353\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology\",\"datePublished\":\"2023-05-29T15:52:00+00:00\",\"dateModified\":\"2024-12-16T15:56:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18353\"},\"wordCount\":261,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Moderna\",\"mRNA\",\"NASDAQ: MRNA\",\"Vaccine\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18353#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18353\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18353\",\"name\":\"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-05-29T15:52:00+00:00\",\"dateModified\":\"2024-12-16T15:56:55+00:00\",\"description\":\"US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district of Shanghai with an investment of USD 100 million. The new unit is controlled by Moderna Biotech UK, and the legal representative is Christoph Brackmann, Moderna\u2019s vice-president of finance, as reported by a local media outlet.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18353#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18353\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18353#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology - Insight, China's Pharmaceutical Industry","description":"US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district of Shanghai with an investment of USD 100 million. The new unit is controlled by Moderna Biotech UK, and the legal representative is Christoph Brackmann, Moderna\u2019s vice-president of finance, as reported by a local media outlet.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18353","og_locale":"en_US","og_type":"article","og_title":"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18353","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-05-29T15:52:00+00:00","article_modified_time":"2024-12-16T15:56:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18353#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18353"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology","datePublished":"2023-05-29T15:52:00+00:00","dateModified":"2024-12-16T15:56:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18353"},"wordCount":261,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Moderna","mRNA","NASDAQ: MRNA","Vaccine"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18353#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18353","url":"https:\/\/flcube.com\/?p=18353","name":"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-05-29T15:52:00+00:00","dateModified":"2024-12-16T15:56:55+00:00","description":"US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district of Shanghai with an investment of USD 100 million. The new unit is controlled by Moderna Biotech UK, and the legal representative is Christoph Brackmann, Moderna\u2019s vice-president of finance, as reported by a local media outlet.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18353#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18353"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18353#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18353"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18353\/revisions"}],"predecessor-version":[{"id":18355,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18353\/revisions\/18355"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}